Literature DB >> 8468273

Second tumors after treatment of childhood malignancies.

L L Robison1, A Mertens.   

Abstract

The occurrence of a second malignancy represents a serious complication of childhood cancer. With the introduction of more intensive multiagent therapy for childhood cancers, not only are a greater proportion of children surviving their initial cancer, but also they now may be at greater risk for developing a second malignancy. The larger studies indicate that the cumulative incidence of second cancers may be as high as 12% at 20 years following the initial cancer. The most consistent finding of the larger studies is that the elevated risk of a second cancer remains relatively constant over time, but the absolute risk increases substantially as the length of follow-up increases. There are treatment-related risk factors, such as solid tumors within irradiated fields and secondary leukemias following alkylating therapy. Retinoblastoma represents one example of the role of genetic predisposition in second cancers. It is imperative that survivors of childhood cancer be closely followed to determine the occurrence of second cancers, particularly those that may occur many years following the original childhood cancer. Research needs to be directed toward the identification of treatment, as well as genetic and life style risk factors. Intervention, through modifications of treatment protocols and implementation of preventive programs, may have a future role in reducing the occurrence of second cancers.

Entities:  

Mesh:

Year:  1993        PMID: 8468273

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  17 in total

1.  Follow-up care for young adult survivors of cancer: lessons from pediatrics.

Authors:  Christine Eiser; Kate Absolom; Diana Greenfield; John Snowden; Robert Coleman; Barry Hancock; Helena Davies
Journal:  J Cancer Surviv       Date:  2007-03       Impact factor: 4.442

2.  Anti-Smoking Communication to Preadolescents with and without a Cancer Diagnosis: Parents and Healthcare Providers as Important Communicators.

Authors:  Leslee Throckmorton-Belzer; Vida L Tyc; Leslie A Robinson; James L Klosky; Shelly Lensing; Andrea K Booth
Journal:  Child Health Care       Date:  2009-10-01

Review 3.  Tumor suppressor genes in molecular medicine.

Authors:  F Hoppe-Seyler; K Butz
Journal:  Clin Investig       Date:  1994-08

Review 4.  Surviving childhood cancer: the impact on life.

Authors:  Robert E Goldsby; Denah R Taggart; Arthur R Ablin
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

5.  Can parents of children with cancer accurately report their child's passive smoking exposure?

Authors:  Vida L Tyc; Shelly Lensing; Christopher M Vukadinovich; Melbourne F Hovell
Journal:  Nicotine Tob Res       Date:  2009-08-20       Impact factor: 4.244

6.  A comparison of tobacco-related risk factors between preadolescents with and without cancer.

Authors:  Vida L Tyc; James L Klosky; Shelly Lensing; Leslee Throckmorton-Belzer; Shesh N Rai
Journal:  J Cancer Surviv       Date:  2009-10-29       Impact factor: 4.442

7.  Provider advice about smoking cessation and pharmacotherapy among cancer survivors who smoke: practice guidelines are not translating.

Authors:  Karen M Emmons; Kim Sprunck-Harrild; Elaine Puleo; Janet de Moor
Journal:  Transl Behav Med       Date:  2013-06       Impact factor: 3.046

8.  Smoking restrictions in the homes of children with cancer.

Authors:  Vida L Tyc; Shelly Lensing; Christopher Vukadinovich; Melbourne F Hovell
Journal:  Am J Health Behav       Date:  2013-07

9.  Predictors of non-participation in a randomized intervention trial to reduce environmental tobacco smoke (ETS) exposure in pediatric cancer patients.

Authors:  James L Klosky; Vida L Tyc; Joanne Lawford; Jason Ashford; Shelly Lensing; Joanna Buscemi
Journal:  Pediatr Blood Cancer       Date:  2009-05       Impact factor: 3.167

10.  Second primary cancers after childhood cancer.

Authors:  L L Robison
Journal:  BMJ       Date:  1996-04-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.